Report
FREE
New opportunities for extended use of Allomap in heart transplant rejection diagnosis
Diaxonhit reported positive results from the CARGO II clinical study for Allomap, a blood test used for heart transplant reĴjection monitoring. The study, conducted on European paĴtients, demonstrated similar results obtained in the previous CARGO I study, performed in the US. Last April, during a symĴposium organized by CareDx and Diaxonhit, interesting data were presented regarding new opportunities for extended use of the Allomap test: a correlation between the Allomap score and patient long-term survival could validate its use as a prognosis test; Allomap combination with a donor-derived cell-free DNA test could improve its performance. Diaxonhit also recently announced the licensing of therapeutic assets to Felicitex Therapeutics that could represent significant upside through upfront and milestones payments, as well as royalties on sales, should the products reach the market. We maintain our valuation of Diaxonhit at €105.2M (Enterprise value). This represents a value of €1.64 per share including estimated net cash of €10.6M.
Underlying
DiaxonHit
Provider
Aurgalys
First French company dedicated to life sciences and healthcare company financing, Aurgalys assists private or listed companies during capital increase, provides equity research or valuation services, takes care of investor relations and assists the management for their strategy and business development. Listing Sponsor Alternext (NYSE Euronext). Conseil en Investissement Financier ORIAS - ACIFTE.
Other Reports on these Companies
Other Reports from Aurgalys
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.